<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449488</url>
  </required_header>
  <id_info>
    <org_study_id>B213</org_study_id>
    <secondary_id>ISRCTN46528154</secondary_id>
    <nct_id>NCT00449488</nct_id>
  </id_info>
  <brief_title>Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction</brief_title>
  <acronym>HEBEIII</acronym>
  <official_title>A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to establish the effects of a single bolus of EPO,
      administered within three hours after a primary PCI for a first acute myocardial infarction,
      on left ventricular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erythropoetin (EPO) is commonly known as an effective treatment for anemia. However, several
      important extra-hematopoeitic effects of EPO are suggested which might be beneficial in the
      setting of an acute myocardial infarction, such as a reduction of apoptosis and stimulation
      of neovascularisation. Recent animal studies provided very consistent evidence for a reduced
      infarct size and improved left ventricular function caused by EPO administration. However,
      clinical studies with EPO in non-anemic patients are scarce.

      We performed a safety study in our department on the effects of a single bolus of EPO in
      patients with an acute myocardial infarction. Serum EPO levels increased a 200-fold and EPO
      administration was not associated with hypertension, nor with an increase in thrombocytes or
      thrombotic events.

      In conclusion, experimental data clearly showed that a single bolus of EPO after the onset of
      an acute myocardial infarction reduced myocardial infarct size, and improved left ventricular
      function. In our safety study, EPO administration in patients with an acute myocardial
      infarction was safe and well tolerated.

      This will be a PROBE (Prospective, Randomised, Open label study with Blinded Endpoint)
      designed study, in wich one group will receive one bolus of EPO 60.000 IU) intravenously
      within 3 hours after the primary PCI procedure and the other group will receive standard
      therapy. After 6 weeks left ventricular ejection fraction will be evaluated by planar
      radionuclide ventriculography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction 6 weeks after primary PCI, measured with planar radionuclide ventriculography</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, myocardial infarct size, and cardiovascular events at 6 weeks after a single bolus of EPO</measure>
    <time_frame>Cardiovascular Events</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">529</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>i.v bolus 60.000 IU epoetin alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <description>epoetin alfa 60.000 IU one i.v. bolus</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Successful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by:

          -  chest pain suggestive for acute myocardial infarction

          -  symptom onset &lt; 12 hour before hospital admission, or &lt; 24 hour in case ongoing
             ischemia

          -  ECG with ST-T segment elevation &gt; 1 mV in 2 or more leads

          -  TIMI flow 0/1 before primary PCI on diagnostic coronary angiography;

        Exclusion Criteria:

          -  Hemoglobin levels &gt; 10.6 mmol/L;

          -  Anticipated additional revascularisation within 4 months;

          -  Cardiogenic shock;

          -  Presence of other serious medical conditions

          -  Pregnancy/breast feeding

          -  Malignant hypertension

          -  End stage renal failure (creatinin &gt; 220 micromol/l)

          -  Previous treatment with rh-EPO

          -  Blood transfusion &lt;12 weeks prior to randomisation

          -  Polycythemia vera

          -  Previous acute myocardial infarction

          -  Concomitant inflammatory or malignant disease

          -  Recent trauma or major surgery

          -  Unwilling to sign informed consent

          -  Atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A A Voors, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Zijlstra, MD,PhD,FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DJ van Veldhuisen, MD,PhD,FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ; HEBE III investigators. Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J. 2008 May;155(5):817-22. doi: 10.1016/j.ahj.2007.12.036.</citation>
    <PMID>18440327</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2007</study_first_submitted>
  <study_first_submitted_qc>March 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>A.A. Voors</name_title>
    <organization>University Medical Center Groningen, department of Cardiology</organization>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>PCI</keyword>
  <keyword>left ventricular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

